Esophageal toxicity of radiation therapy: Clinical risk factors and management;Toxicité œsophagienne de la radiothérapie : Clinique, facteurs de risque et prise en charge

Cancer/Radiotherapie

Volumn 16, Issue 5-6, 2012, Pages 364-371

  Challand, T ^a   Thureau, S ^a   Dubray, B ^a   Giraud, P ^b,c  

^a CENTRE HENRI BECQUEREL   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

Acute radiation induced esophagitis; Lung cancer; Radiotherapy; Toxicity

Indexed keywords

AGE; ANALGESIA; BODY MASS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; DISEASE SEVERITY; DYSPHAGIA; ENTERIC FEEDING; ESOPHAGITIS; GASTROESOPHAGEAL REFLUX; HUMAN; IRRADIATION; LUNG CANCER; ODYNOPHAGIA; PRIORITY JOURNAL; RADIATION DOSE; RADIATION INJURY; RADIATION PROTECTION; RISK FACTOR; SEX DIFFERENCE; SHORT SURVEY;

ANALGESICS; DIET; ESOPHAGEAL STENOSIS; ESOPHAGITIS; HUMANS; PROTON PUMP INHIBITORS; RADIATION-PROTECTIVE AGENTS; RADIOTHERAPY; RADIOTHERAPY DOSAGE; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 84866355178     PISSN: 12783218     EISSN: 17696658     Source Type: Journal    
DOI: 10.1016/j.canrad.2012.07.180     Document Type: Short Survey

References (54)

1. Senkus-Konefka E., Jassem J. Complications of breast-cancer radiotherapy. Clin Oncol (R Coll Radiol) 2006, 18:229-235.
2. Daly J.M., Fry W.A., Little A.G., Winchester D.P., McKee R.F., Stewart A.K., et al. Esophageal cancer: results of an American College of Surgeons Patient Care Evaluation Study. J Am Coll Surg 2000, 190:562-572.
3. Cancer Therapy Evaluation Program [Site internet]. Common Terminology Criteria for Adverse Events (CTCAE) and Common Toxicity Criteria (CTC). Bethesda, MD: National Cancer Institute. Consultable sur: (accès le 20 mars 2012). http://ctep.cancer.gov/reporting/ctc.html.
4. La T.H., Minn A.Y., Su Z., Fisher G.A., Ford J.M., Kunz P., et al. Multimodality treatment with intensity modulated radiation therapy for esophageal cancer. Dis Esophagus 2010, 23:300-308.
5. Belderbos J.S., De Jaeger K., Heemsbergen W.D., Seppenwoolde Y., Baas P., Boersma L.J., et al. First results of a phase I/II dose escalation trial in non-small cell lung cancer using three-dimensional conformal radiotherapy. Radiother Oncol 2003, 66:119-126.
6. Furuse K., Fukuoka M., Kawahara M., Nishikawa H., Takada Y., Kudoh S., et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999, 17:2692-2699.
7. Jones J.A., Avritscher E.B., Cooksley C.D., Michelet M., Bekele B.N., Elting L.S. Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer. Support Care Cancer 2006, 14:505-515.
8. Koukourakis M., Hlouverakis G., Kosma L., Skarlatos J., Damilakis J., Giatromanolaki A., et al. The impact of overall treatment time on the results of radiotherapy for nonsmall cell lung carcinoma. Int J Radiat Oncol Biol Phys 1996, 34:315-322.
9. Machtay M., Hsu C., Komaki R., Sause W.T., Swann R.S., Langer C.J., et al. Effect of overall treatment time on outcomes after concurrent chemoradiation for locally advanced non-small-cell lung carcinoma: analysis of the Radiation Therapy Oncology Group (RTOG) experience. Int J Radiat Oncol Biol Phys 2005, 63:667-671.
10. Orlando R.C. The integrity of the esophageal mucosa. Balance between offensive and defensive mechanisms. Best Pract Res Clin Gastroenterol. 2010, 24:873-882.
11. Choy H., LaPorte K., Knill-Selby E., Mohr P., Shyr Y. Esophagitis in combined modality therapy for locally advanced non-small cell lung cancer. Semin Radiat Oncol 1999, 9:90-96.
12. Caillot É., Denis F. Mucites radioinduites buccopharyngées : actualités sur la prise en charge. Cancer Radiother 2012, [http://dx.doi.org/10.1016/j.canrad.2012.05.005 (ce numéro)].
13. Rose J., Rodrigues G., Yaremko B., Lock M., D'Souza D. Systematic review of dose-volume parameters in the prediction of esophagitis in thoracic radiotherapy. Radiother Oncol 2009, 91:282-287.
14. Hirota S., Tsujino K., Hishikawa Y., Watanabe H., Kono K., Soejima T., et al. Endoscopic findings of radiation esophagitis in concurrent chemoradiotherapy for intrathoracic malignancies. Radiother Oncol 2001, 58:273-278. [Erratum in: Radiother Oncol 2001;60(1):107].
15. Werner-Wasik M., Pequignot E., Leeper D., Hauck W., Curran W. Predictors of severe esophagitis include use of concurrent chemotherapy, but not the length of irradiated esophagus: a multivariate analysis of patients with lung cancer treated with nonoperative therapy. Int J Radiat Oncol Biol Phys 2000, 48:689-696.
16. Davila M., Bresalier R.S. Gastrointestinal complications of oncologic therapy. Nat Clin Pract Gastroenterol Hepatol 2008, 5:682-696.
17. Blijlevens N.M., Donnelly J.P., Yakar D., van Die C.E., de Witte T. Determining mucosal barrier injury to the oesophagus using CT scan. Support Care Cancer 2007, 15:1105-1108.
18. Byhardt R.W., Scott C., Sause W.T., Emami B., Komaki R., Fisher B., et al. Response, toxicity, failure patterns, and survival in five Radiation Therapy Oncology Group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small-cell carcinoma of the lung. Int J Radiat Oncol Biol Phys 1998, 42:469-478.
19. Maguire P.D., Sibley G.S., Zhou S.M., Jamieson T.A., Light K.L., Antoine P.A., et al. Clinical and dosimetric predictors of radiation-induced esophageal toxicity. Int J Radiat Oncol Biol Phys 1999, 45:97-103.
20. Singh A.K., Lockett M.A., Bradley J.D. Predictors of radiation-induced esophageal toxicity in patients with non-small-cell lung cancer treated with three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 2003, 55:337-341.
21. Bradley J., Deasy J.O., Bentzen S., El-Naqa Dosimetric correlates for acute esophagitis in patients treated with radiotherapy for lung carcinoma. Int J Radiat Oncol Biol Phys 2004, 58:1106-1113.
22. Patel A.B., Edelman M.J., Kwok Y., Krasna M.J., Suntharalingam M. Predictors of acute esophagitis in patients with non-small-cell lung carcinoma treated with concurrent chemotherapy and hyperfractionated radiotherapy followed by surgery. Int J Radiat Oncol Biol Phys 2004, 60:1106-1112.
23. Chapet O., Kong F.M., Lee J.S., Hayman J.A., Ten Haken R.K. Normal tissue complication probability modeling for acute esophagitis in patients treated with conformal radiation therapy for non-small cell lung cancer. Radiother Oncol 2005, 77:176-181.
24. Qiao W.B., Zhao Y.H., Zhao Y.B., Wang R.Z. Clinical and dosimetric factors of radiation-induced esophageal injury: radiation-induced esophageal toxicity. World J Gastroenterol 2005, 11:2626-2629.
25. Belderbos J., Heemsbergen W., Hoogeman M., Pengel K., Rossi M., Lebesque J. Acute esophageal toxicity in non-small cell lung cancer patients after high dose conformal radiotherapy. Radiother Oncol 2005, 75:157-164.
26. Kim T.H., Cho K.H., Pyo H.R., Lee J.S., Han J.Y., Zo J.I., et al. Dose-volumetric parameters of acute esophageal toxicity in patients with lung cancer treated with three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 2005, 62:995-1002.
27. Ahn S.J., Kahn D., Zhou S., Yu X., Hollis D., Shafman T.D., et al. Dosimetric and clinical predictors for radiation-induced esophageal injury. Int J Radiat Oncol Biol Phys 2005, 61:335-347.
28. Senan S., De Ruysscher D., Giraud P., Mirimanoff R., Budach V. Literature-based recommendations for treatment planning and execution in high-dose radiotherapy for lung cancer. Radiother Oncol 2004, 71:139-146. Radiotherapy Group of European Organization for Research and Treatment of Cancer.
29. Kahn D., Zhou S., Ahn S.J., Hollis D., Yu X., D'Amico T.A., et al. "Anatomically-correct" dosimetric parameters may be better predictors for esophageal toxicity than are traditional CT-based metrics. Int J Radiat Oncol Biol Phys 2005, 62:645-651.
30. Dieleman E.M., Senan S., Vincent A., Lagerwaard F.J., Slotman B.J., van Sörnsen de Koste J.R. Four-dimensional computed tomographic analysis of esophageal mobility during normal respiration. Int J Radiat Oncol Biol Phys 2007, 67:775-780.
31. Grills I.S., Yan D., Martinez A.A., Vicini F.A., Wong J.W., Kestin L.L. Potential for reduced toxicity and dose escalation in the treatment of inoperable non-small-cell lung cancer: a comparison of intensity-modulated radiation therapy (IMRT), 3D conformal radiation, and elective nodal irradiation. Int J Radiat Oncol Biol Phys 2003, 57:875-890.
32. Yuan S., Sun X., Li M., Yu J., Ren R., Yu Y., et al. A randomized study of involved-field irradiation versus elective nodal irradiation in combination with concurrent chemotherapy for inoperable stage III nonsmall cell lung cancer. Am J Clin Oncol 2007, 30:239-244.
33. Langer C.J., Movsas B., Hudes R., Schol J., Keenan E., Kilpatrick D., et al. Induction paclitaxel and carboplatin followed by concurrent chemoradiotherapy in patients with unresectable, locally advanced non-small cell lung carcinoma: report of Fox Chase Cancer Center study 94-001. Semin Oncol 1997, 24. S12-89-95.
34. Rosenman J.G., Halle J.S., Socinski M.A., Deschesne K., Moore D.T., Johnson, et al. High-dose conformal radiotherapy for treatment of stage IIIA/IIIB non-small-cell lung cancer: technical issues and results of a phase I/II trial. Int J Radiat Oncol Biol Phys 2002, 54:348-356.
35. Takeda K., Nemoto K., Saito H., Ogawa Y., Takai Y., Yamada S. Dosimetric correlations of acute esophagitis in lung cancer patients treated with radiotherapy. Int J Radiat Oncol Biol Phys 2005, 62:626-629.
36. Wei X., Liu H.H., Tucker S.L., Liao Z., Hu C., Mohan R., et al. Risk factors for acute esophagitis in non-small-cell lung cancer patients treated with concurrent chemotherapy and three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 2006, 66:100-107.
37. Rodríguez N., Algara M., Foro P., Lacruz M., Reig A., Membrive, et al. Predictors of acute esophagitis in lung cancer patients treated with concurrent three-dimensional conformal radiotherapy and chemotherapy. Int J Radiat Oncol Biol Phys 2009, 73:810-817.
38. Chapet O. Complications aiguës et tardives des irradiations thoraciques. Cancer Radiother 2007, 11:92-100.
39. Werner-Wasik M., Yorke E., Deasy J., Nam J., Marks L.B. Radiation dose-volume effects in the esophagus. Int J Radiat Oncol Biol Phys 2010, 76:S86-S93.
40. Leignel Argo D., Giraud P. Non small cell lung cancer. Cancer Radiother 2010, 14:S61-S73.
41. Zhu J., Zhang Z.C., Li B.S., Liu M., Yin Y., Yu J.M., et al. Analysis of acute radiation-induced esophagitis in non-small-cell lung cancer patients using the Lyman NTCP model. Radiother Oncol 2010, 97:449-454.
42. Chapet O., Thomas E., Kessler M.L., Fraass B.A., Ten Haken R.K. Esophagus sparing with IMRT in lung tumor irradiation: an EUD-based optimization technique. Int J Radiat Oncol Biol Phys 2005, 63:179-187.
43. Sur R.K., Kochhar R., Singh D.P. Oral sucralfate in acute radiation oesophagitis. Acta Oncol 1994, 33:61-63.
44. McGinnis W.L., Loprinzi C.L., Buskirk S.J., Sloan J.A., Drummond R.G., Frank A.R., et al. Placebo-controlled trial of sucralfate for inhibiting radiation-induced esophagitis. J Clin Oncol 1997, 15:1239-1243.
45. Leong S.S., Tan E.H., Fong K.W., Wilder-Smith E., Ong Y.K., Tai B.C., et al. Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small-cell lung cancer. J Clin Oncol 2003, 21:1767-1774.
46. Movsas B., Scott C., Langer C., Werner-Wasik M., Nicolaou N., Komaki, et al. Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01. J Clin Oncol 2005, 23:2145-2154.
47. Sasse A.D., Clark L.G., Sasse E.C., Clark O.A. Amifostine reduces side effects and improves complete response rate during radiotherapy: results of a meta-analysis. Int J Radiat Oncol Biol Phys 2006, 64:784-791.
48. Peterson D.E., Bensadoun R.J., Roila F. Management of oral and gastrointestinal mucositis: ESMO Clinical Practice Guidelines. Ann Oncol 2010, 21:v261-v265. ESMO Guidelines Working Group.
49. Bensadoun R.J., Schubert M.M., Lalla R.V., Keefe D. Amifostine in the management of radiation-induced and chemo-induced mucositis. Support Care Cancer 2006, 14:566-572.
50. Keefe D.M., Sonis S.T., Bowen J.M. Emerging drugs for chemotherapy-induced mucositis. Expert Opin Emerg Drugs 2008, 13:511-522.
51. Algara M., Rodríguez N., Viñals P., Lacruz M., Foro P., Reig A., et al. Prevention of radiochemotherapy-induced esophagitis with glutamine: results of a pilot study. Int J Radiat Oncol Biol Phys 2007, 69:342-349.
52. Berkey F.J. Managing the adverse effects of radiation therapy. Am Fam Physician 2010, 82:381-388. 394.
53. de Wijkerslooth L.R., Vleggaar F.P., Siersema P.D. Endoscopic management of difficult or recurrent esophageal strictures. Am J Gastroenterol 2011, 106:2080-2091. [quiz 2092. doi:10.1038/ajg.2011.348].
54. Bera G., Pointreau Y., Denis F., Orain I., Dupuis O., Créhange G. Dose de tolérance à l'irradiation des tissus sains: l'œsophage. Cancer Radiother 2010, 14:327-335.